IVS-1001 is under clinical development by Invectys and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect IVS-1001’s likelihood of approval (LoA) and phase transition for Squamous Non-Small Cell Lung Cancer took place on 19 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their IVS-1001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

IVS-1001 overview

UCPVax is under development for the treatment of metastatic squamous cell non-small cell lung cancer, glioblastoma multiforme, lung adenocarcinoma, HPV positive cancers including advanced or metastatic anal cancer, head and neck squamous cell carcinoma, cervical and vulvar cancer and large cell carcinoma. The vaccine candidate is administered through subcutaneous route. It is composed of two peptides called UCP2 and UCP4 of 15 to 20 amino acids (universal cancer peptides-UCP) derived from telomerase reverse transcriptase (TERT) protein. The vaccine candidate is based on telomerase gene technology.

Invectys overview

Invectys is a biopharmaceutical company that develops immunotherapy to treat cancer. The company product pipeline includes INVAC-1, a DNA vaccine targeting Telomerase; Universal Cancer Peptide vaccine UCPVax. It offers products such as a human telomerase peptide-based vaccine; INMAB-1, a monoclonal antibody; and TelVet, dog telomerase DNA-based anti-cancer vaccine similar to INVAC-1. Invectys TelVet is developed for the treatment of pet cancers such as dog cancers. The company’s technology restores and mobilizes the anti-tumor ability of the immune system of cancer patients. Invectys is headquartered in Paris, Ile-de-France, France

Quick View IVS-1001 LOA Data

Report Segments
  • Innovator
Drug Name
  • IVS-1001
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.